Illustration: Eniola Odetunde/Axios
Claris Bio, which is developing a corneal disease treatment, raised a $118 million Series B, new CEO Stephen Brady tells Axios Pro.
Why it matters: The funding gives the single-asset biotech enough runway to carry on after its planned late-stage trials.
